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Practical chromatography-free synthesis of 2-iodo-N,N-diisopropyl-
ferrocenecarboxamide and further transformations 
 
Abstract An efficient procedure able to deliver grams of racemic and 
enantioenriched 2-iodo-N,N-diisopropylferrocenecarboxamide without 
chromatographic purification was developed. To introduce the halogen, two 
procedures, one using the nBuLi-TMEDA chelate and one using a lithium amide 
in the presence of ZnCl2 as in situ trap were developed. Further 
functionalization by Suzuki-Miyaura and Ullman-type cross-couplings was 
investigated to access a variety of ferrocene derivatives. 
Key words Ferrocene, carboxamide, large scale synthesis, deprotometalation, 
Suzuki-Miyaura cross-coupling, Ullmann-type cross-coupling 
 
Discovered in 1951, ferrocene is currently one of the most 
important organometallic scaffolds with multiple applications in 
redox sensing, catalysis, materials science and medicinal 
chemistry.1 Due to its planar chirality when two different 
substituents are located on the same ring of a ferrocene, the 
search for asymmetric syntheses has been a recurring question 
in metallocene science.2 The diastereoselective ortho-
deprotometalation (DoM) is a powerful methodology but implies 
multiple steps to install and remove, when possible, the chiral 
directing group. Therefore, only a few directing groups are 
usually used in this strategy.3 Enzymatic and chemical kinetic 
resolution have been investigated with various levels of success 
but are not general.4 Recent years have witnessed the emergence 
of catalytic asymmetric ferrocene C-H bond activation.5 However, 
due to the use of an expensive catalytic system and, although 
growing, still limited functionalization scope, this approach 
remains limited. The enantioselective DoM of monosubstituted 
ferrocenes is another approach which relies on the ability of a 
chiral base to discriminate between both enantiotopic protons. 
Although various substrates have been evaluated over the years,6 
N,N-diisopropylferrocenecarboxamide (1) afforded the best 
results when treated with the nBuLi-(_)-sparteine chelate before 
interception with an electrophile.7 Even if the availability and 
prices of sparteine enantiomers have varied over time, (+)-
sparteine has remained the most expensive for a long period.8 
Therefore, the use of O’Brien’s (+)-sparteine surrogate was 
required to deliver the opposite enantiomer of 2-substituted 
ferrocenecarboxamide with high level of stereocontrol.9 It should 
be pointed out that, though 1 has mainly been functionalized by 
deprotolithiation, its deproto-mercuration,10 -cupration11 and –
zincation12 have also be reported to prepare compounds that are 
otherwise hardly accessible. 
In the frame of our ongoing research program dedicated to the 
synthesis of original ferrocene derivatives,13 we required large 
quantities of 2-iodo-N,N-diisopropylferrocenecarboxamide (2) 
in both racemic and enantioenriched forms. Although already 
reported in the literature, the protocols relying on 
chromatographic purification were not compatible with the scale 
required here. 
Here we describe the chromatography-free large scale synthesis 
of (±)-2 and the gram-scale synthesis of (Sp)-2 (Scheme 1). The 
usefulness of 2 in organic synthesis was further demonstrated by 
its functionalization through palladium-catalyzed Suzuki-
Miyaura and copper-mediated Ullmann-type cross-couplings.   
 
Scheme 1 Gram-scale synthesis of (±)- and (Sp)-2 and their further 
functionalization. 
Commercially available ferrocenecarboxylic acid (3) remaining 
expensive, our synthesis starts from ferrocene, which is 
metallated using an excess of tBuLi in the presence of a catalytic 
amount of tBuOK, as described by Mueller-Westerhoff (Scheme 
2).14 Upon metallation completion, gaseous carbon dioxide is 
passed through the reaction mixture to afford, after acidic work-
up, ferrocenecarboxylic acid (3) in 94% yield (34 g in a single 
batch). It was subsequently converted into N,N-
diisopropylferrocenecarboxamide (1) by a two-step process: 
formation of the acyl chloride by treatment with an excess of 
oxalyl chloride in the presence of catalytic amounts of 
dimethylformamide (DMF) and reaction with diisopropylamine. 
In our optimized protocol, which does not require anhydrous 
conditions, the crude product can be obtained in a couple of 
hours. Usually purified by column chromatography, we found 
that a simple recrystallization of the crude reaction mixture from 
heptane affords analytically pure product in 95.5% yield. 
Racemic deprotometalation of compound 1 can be performed 
using nBuLi in the presence of N,N,N’,N’-
tetramethylethylenediamine (TMEDA) to enhance its reactivity 
in diethyl ether. We briefly studied the possibility to carry out this 
transformation with the more reactive sBuLi in THF at -78 °C; 
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however, moderate yields (68% on average), resulting from the 
formation of multiple by-products, were obtained. Therefore, the 
deprotometalation with the nBuLi-TMEDA chelate in diethyl 
ether at cryogenic temperature was performed, followed by 
iodine interception. After a traditional work-up and removal of 
insoluble by-products, a simple recrystallization allowed the 
isolation of 36 g of the title product (±)-2 in a single batch (88% 
yield). 
For practical reasons, we have also developed another large scale 
synthesis of (±)-2 by following the in situ trapping strategy.15 
Therefore, we reacted 1 with LiTMP (TMP = 2,2,6,6-
tetramethylpiperidide) in the presence of anhydrous ZnCl2 as the 
in situ trap in THF before interception with iodine. By following a 
similar work-up and crystallization purification protocol, we 
isolated 20 g of (±)-2 in a single batch (93% yield). 
 
Scheme 2 Column chromatography-free multi-gram synthesis of compound 
(±)-2. 
Having established a reliable multi-gram access toward (±)-2, we 
turned our attention to its enantioenriched form. As the use of 
O’Brien’s (+)-sparteine surrogate has not yet been attempted on 
1, we thought it interesting to secure this way. However, and even 
though (+)-sparteine surrogate is easily available from natural 
sources,16 performing the asymmetric deprotometalation of 1 at 
a scale similar to that of the racemic one was economically not 
viable. By following O’Brien’s protocol,9 we therefore prepared 
1.4 g of (Sp)-2 (69% yield) with an enantiomeric ratio (er) of 96:4 
as determined by chiral HPLC (Scheme 3). Interestingly, a simple 
recrystallization increases the er up to 99:1. Initially inferred by 
optical rotation measurement, the absolute configuration of (Sp)-
2 was confirmed by X-ray diffraction analysis (see SI). 
 
Scheme 3 Enantioselective synthesis of compound (Sp)-2. 
Therefore, assuming that (_)-sparteine or (+)-sparteine surrogate 
are accessible in sufficient quantities, ten or so grams of the 
enantioenriched ferrocene 2 can be prepared in a few days 
without recurring to chromatographic purification. This is 
especially relevant with the (+)-sparteine surrogate which can be 
used in catalytic amount without major drop in the er. 
Although we previously demonstrated the usefulness of 2 to 
access original 3-iodo-N,N-diisopropylferrocenecarboxamide 
through a halogen ‘dance’ reaction,13, 17 the functionalization of 
the former was not extensively studied. In 2014, Kumar has 
reported an original example of a tBuOK-mediated sp3 C-H bond 
functionalization to access lactams in 96% yield from (±)-2.18 
Earlier, Snieckus showed that the Suzuki-Miyaura cross-coupling 
of (Rp)-2 under aqueous conditions afforded the desired biaryl 
product in low yield but with unchanged enantiomeric ratio 
(31% yield, 98:2 er).7 More recently, Anderson showed the ability 
of Cu2O to perform an Ullmann-type cross-coupling between 
(Rp)-2 and either phthalimide or acetic acid.19 The positive 
optical rotation recorded clearly indicated that enantioenriched 
products were obtained but without further indication of the 
enantiomeric ratio. 
Therefore, we thought it interesting to apply Suzuki-Miyaura 
reaction conditions able to deliver the desired products in higher 
yields. The full transfer of chiral information being already 
reported, we focussed our study on racemic compounds. As 
aqueous reaction conditions seem to promote dehalogenation 
instead of the desired coupling reaction on such substrates, we 
successfully switched to anhydrous conditions. Therefore, 
reacting (±)-2 with phenylboronic acid in the presence of 
Pd(dba)2 (dba = dibenzylideneacetone), PPh3 and CsF in toluene 
smoothly afforded the title product (±)-4 in 58% yield (Scheme 
4). Following the general reactivity trend of boronic acids in the 
Suzuki-Miyaura cross-coupling,20 the electron-rich ones afforded 
higher yields (compounds (±)-5-7), while a major yield drop was 
noticed with the chlorinated and trifluoromethylated ones 
(compounds (±)-8-10). In these cases, moderate conversions as 
well as competitive dehalogenation were noticed. The use of 
ferroceneboronic acid,21 2-thienylboronic acid or 4-
nitrophenylboronic acid only led to recovery of starting material 
or degradation. 
 
Scheme 4 Suzuki-Miyaura cross-coupling between (±)-2 and various boronic 
acids. 
Advanced NMR studies and X-ray diffraction analyses revealed 
similar structures in solution and in the solid state, probably due 
to the reduced degree of freedom for steric reasons (see SI). As a 
result, all peaks of the 1H NMR spectra of compounds (±)-4-10 
are well resolved while the isopropyl signals are usually broad 
singlets in the ferrocenecarboxamide series. In all studied cases, 
the phenyl ring appears tilted relative to the Cp ring while the 
C=O bond of the amide always points down toward the iron atom. 
Furthermore, one methyl of each isopropyl group points toward 
the aromatic ring while the other points toward the ferrocene 
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moiety. Depending on the substituent on the phenyl ring, some 
degree of rotation around the FcC-ArC bond was noticed. 
To complete this study, we finally extended the scope of the 
copper-mediated C-O bond formation between 2 and carboxylic 
acids. When reacting (±)-2 with a slight excess of 4-fluorobenzoic 
acid in the presence of Cu2O, we isolated (±)-11 in 85% yield 
(Scheme 5). Similarly, from (Sp)-2 (87:13 er), (Sp)-11 was 
obtained in 76% yield and almost unchanged er ratio (89:11). 
Having established the full transfer of chiral information, we 
evaluated the reaction between (±)-2 and other coupling 
partners. 2-Naphthoic, 2,4-dimethylbenzoic and 2-
acetoxybenzoic acids all afforded the corresponding esters (±)-
12-14 in good yields while terephthalic acid led to the bis-ester 
(±)-15 in 49% yield. The reaction was also found to be 
compatible with ferrocenecarboxylic and 2-thiophenecarboxylic 
acids (products (±)-16 and (±)-17, respectively). However, 2-
picolinic acid and phenylpropiolic acids only led to recovery of 
starting material. Finally, acrylic acid derivatives such as 3,4-
methylenedioxycinnamic acid and piperic acid were successfully 
converted into the corresponding esters (±)-18 and (±)-19 (88% 
and 92% yield, respectively).  
 
Scheme 5 Ullmann-type cross-coupling between (±)-2 or (Sp)-2 and various 
carboxylic acids. 
In conclusion, we have reported reaction conditions able to 
deliver grams of 2-iodo-N,N-diisopropylferrocenecarboxamide 
(±)- or (Sp)-2 from cheap ferrocene without chromatographic 
purification. Two protocols, one using the nBuLi-TMEDA chelate 
and one using LiTMP in the presence of ZnCl2 as an in situ trap 
were therefore successfully developed. Further elaboration 
through Suzuki-Miyaura or Ullmann-type cross-coupling 
reactions afforded biarylic and ester derivatives in moderate to 
good yields. 
 
 
General Considerations. Unless otherwise stated, all the reactions were 
performed under an argon atmosphere with anhydrous solvents using 
Schlenk technics. THF and Et2O were distilled over sodium-
benzophenone, acetonitrile and toluene were distilled over CaH2. Unless 
otherwise stated, all reagents were used without prior purification. All 
organolithiated reagents were titrated before use.22 tBuOK (99.99% 
quality) was purchased from Sigma-Aldrich and used without further 
purification. Column chromatography separations were achieved on silica 
gel (40-63 μm). All Thin Layer Chromatographies (TLC) were performed 
on aluminum backed plates pre-coated with silica gel (Merck, Silica Gel 60 
F254). They were visualized by exposure to UV light. Melting points were 
measured on a Kofler bench. IR spectra were taken on a Perkin-Elmer 
Spectrum 100 spectrometer. 1H and 13C Nuclear Magnetic Resonance 
(NMR) spectra were recorded either (i) on a Bruker Avance III 
spectrometer at 300 MHz and 75.4 MHz, respectively, or (iii) on a Bruker 
Avance III HD at 500 MHz and 126 MHz, respectively. 1H chemical shifts 
(δ) are given in ppm relative to the solvent residual peak and 13C chemical 
shifts are relative to the central peak of the solvent signal. Cp refers to the 
unsubstituted cyclopentadienyl ring on ferrocene. Optical rotations were 
recorded at 20 °C on a Perkin Elmer 341 polarimeter. Enantiomeric ratios 
(er) were determined by chiral HPLC on a ThermoFischer Ultimate 3000 
apparatus. ZnCl2 was recrystallized from dioxane in the presence of zinc 
dust and dried under high vacuum at 150 °C overnight. (+)-Sparteine 
surrogate was prepared according to O’Brien and was distilled over CaH2 
before use.16 Piperic acid was prepared according to Singh.23 
Safety Considerations. Due to its high pyrophoric character, tBuLi needs 
to be used only under inert conditions (anhydrous, nitrogen or argon 
atmosphere) and by people well trained to the manipulation of reactive 
organometallics. Due to the inherent dangers of using cryogenic 
temperatures, experiments should be performed by well-trained people.  
Procedures 
Ferrocenecarboxylic acid (3) 
[CAS Reg. No. 1271-42-7] 
Ferrocene (29.8 g, 160 mmol, 1.00 equiv) and tBuOK (1.79 g, 16.0 mmol, 
0.100 equiv) were introduced into a 2 L flame-dried round-bottom flask 
which was then subjected to three cycles of vacuum/argon. Anhydrous 
THF (1.23 L) was introduced by cannula and the reaction mixture was 
stirred at rt until dissolution of all solids. The reaction mixture was cooled 
between -85 and -80 °C (external temperature) in an acetone/liquid 
nitrogen bath. tBuLi (1.6 M, 320 mmol, 200 mL, 2.00 equiv) was then 
introduced dropwise by cannula keeping the temperature of the bath 
between -85 and -80 °C. After addition, the reaction mixture was stirred 
at the same temperature for 1 h. Gaseous CO2 (dried by bubbling through 
concentrated H2SO4 and passing through an anhydrous CaCl2 column) was 
bubbled into the reaction mixture for 30 min, keeping the temperature of 
the bath between -85 and -80 °C. The reaction mixture was then allowed 
to warm to -15 °C, keeping the flask into the bath, with a continued 
bubbling of CO2. At -15 °C, bubbling of CO2 was stopped, the cooling bath 
was removed and the reaction mixture was warmed to rt. Water (200 mL) 
was slowly added to the reaction mixture which was then extracted with 
10% NaOH (6 x 150 mL). The combined aqueous layers were backwashed 
with Et2O (4 x 250 mL), cooled to 0 °C (ice-water bath) and acidified with 
HCl (35%) until pH 1 was reached. Caution: vigorous evolution of CO2 
occurred upon acidification. The resulting solids were filtered on a 
sintered-glass funnel (porosity 3), washed with water (5 x 250 mL) and 
pentane (1 x 250 mL), wringing the solid under vacuum between each 
wash. The resulting solid was dried overnight under high-vacuum (2 
mbar) using P2O5 trap to give the title product as an orange solid (34.6 g, 
94%). Rf (PET-EtOAc 75:25) = 0.30. Mp 208-210 °C (decomp.). Analytical 
data analogous to those reported previously.24 
νmax (film)/cm−1 2882 (br), 1651, 1474, 1282, 1158, 1029, 936, 914, 834, 
740. 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 12.15 (br s, 1H, CO2H), 4.69 (s, 2H, 
2 x FcCH), 4.43 (s, 2H, 2 x FcCH), 4.21 (s, 5H, Cp). 
13C NMR (126 MHz, DMSO-d6): δ (ppm) 172.1 (CO2H), 71.8 (FcC), 71.0 (2 
x FcCH), 69.9 (2 x FcCH), 69.5 (Cp). 
N,N-Diisopropylferrocenecarboxamide (1) 
[CAS Reg. No. 169830-46-0] 
Compound 3 (27.6 g, 120 mmol, 1.00 equiv) was introduced into a 1 L 
round-bottom flask equipped with a bubbler and an addition funnel. 
CH2Cl2 (undried standard quality, 480 mL) and dimethylformamide 
(undried standard quality, 0.50 mL, 425 mg, 5.80 mmol, 50.0 equiv) were 
introduced and the resulting orange suspension was stirred at rt. Oxalyl 
chloride (25.4 mL, 38.1 g, 300 mmol, 2.50 equiv) was added dropwise over 
20 min. Caution: evolution of CO and CO2 required to work under a well-
ventilated fume hood. After addition, the addition funnel was washed with 
CH2Cl2 (10.0 mL) and the reaction mixture was then stirred at rt for 30 
min. Remark: as the reaction proceeds, the orange solid slowly dissolves 
leading to a dark-red solution of FcCOCl. All volatiles were removed under 
vacuum using a rotary evaporator and the resulting oil was kept under 
high vacuum (2 mbar) for 5 min before being dissolved in CH2Cl2 (undried 
standard quality, 480 mL). Diisopropylamine (50.5 mL, 36.4 g, 360 mmol, 
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3.00 equiv) was added dropwise over 30 min. Caution: a slightly 
exothermic reaction was noticed, however not high enough for solvent 
boiling. After addition, the reaction mixture was stirred for an additional 
30 min at rt. All volatiles were removed under vacuum using a rotary 
evaporator and the resulting oil was kept under high vacuum (2 mbar) for 
5 min. Et2O (500 mL) was added and the reaction mixture was washed 
with HCl (1.0 M aq., 150 mL). Remark: in case of emulsion formation, 
filtration over cotton wool can be done. The aqueous layer was 
backwashed with Et2O (100 mL). The combined organic layers were 
washed with NaOH (5%, 150 mL), water (150 mL), brine (150 mL), dried 
over MgSO4, filtered over a pad of Celite (⌀ 6, h 4 cm, sintered glass funnel 
porosity 3) and concentrated under vacuum to give the crude product. 
The residue was transferred into a 250 mL round-bottom flask using 
heptane (65 mL). The solution was heated at reflux, allowed to cool to rt 
and then kept at -20 °C overnight. Using a cannula, the solution was 
pumped off from the solid which was washed with cooled pentane (-30 °C, 
1 x 15 mL). The resulting solid was dried under high-vacuum (2 mbar) to 
give the title product as an orange solid (35.9 g, 95.5%). Rf (eluent: PET-
EtOAc 75:25) = 0.65. Mp 73-75 °C. Analytical data analogous to those 
reported previously.13 
νmax (film)/cm−1 3084, 2972, 1627, 1463, 1423, 1369, 1317, 1200, 1151, 
1135, 1105, 1041, 1025, 823, 806. 
1H NMR (500 MHz, CDCl3): δ (ppm) 4.58 (br s, 1H, CH), 4.52 (t, J = 1.7 Hz, 
2H, 2 x FcCH), 4.22 (t, J = 1.7 Hz, 2H, 2 x FcCH), 4.19 (s, 5H, Cp), 3.38 (br s, 
1H, CH), 1.44 (br s, 6H, 2 x CH3), 1.18 (br s, 6H, 2 x CH3). 
13C NMR (126 MHz, CDCl3): δ (ppm) 169.5 (C=O), 81.4 (FcC), 70.1 (2 x 
FcCH), 69.8 (Cp), 68.9 (2 x FcCH), 49.6 (CH), 46.4 (CH), 21.3 (4 x CH3). 
 Mass: 313 [M], 213 [M-NiPr2]. 
(±)-2-iodo-N,N-diisopropylferrocenecarboxamide ((±)-2) by using 
nBuLi-TMEDA 
[CAS Reg. No. 344927-04-4] 
TMEDA (21.0 mL, 16.3 g, 140 mmol, 1.50 equiv, freshly distilled over CaCl2 
and stored over KOH pellets) and anhydrous Et2O (430.0 mL) were 
introduced into a 2 L flame-dried round-bottom flask under argon. The 
reaction mixture was cooled to between -85 and -80 °C (external 
temperature) in an acetone/liquid nitrogen bath. nBuLi (1.4 M, 100 mL, 
140 mmol, 1.50 equiv) was then introduced dropwise by cannula, keeping 
the temperature of the bath between -85 and -80 °C. After addition, the 
reaction mixture was stirred at the same temperature for 15 min. 
Compound 2 (29.2 g, 93.3 mmol, 1.00 equiv) was introduced into a 
separate 1 L flame-dried round-bottom flask which was subjected to three 
cycles of vacuum/argon. Anhydrous Et2O (430 mL) was added and the 
solution was stirred until dissolution of all solids. The solution of 1 was 
transferred into the nBuLi-TMEDA solution dropwise by cannula, keeping 
the temperature of the bath between -85 and -80 °C. The flask was washed 
with 10.0 mL of anhydrous Et2O, also transferred by cannula. After 
addition, the reaction mixture was stirred at the same temperature for 1 
h. Iodine (47.4 g, 187 mmol, 2.00 equiv) was introduced in a separate 1 L 
flame-dried round-bottom flask under argon and was dissolved into 
anhydrous Et2O (800 mL). The iodine solution was transferred to the 
lithioferrocene solution dropwise by cannula, keeping the temperature of 
the bath between -85 and -80 °C. The flask was washed with 10.0 mL of 
anhydrous Et2O, also transferred by cannula. The reaction mixture was 
then allowed to warm to -15 °C, keeping the flask into the bath. At -15 °C, 
the cooling bath was removed and the reaction mixture was warmed to rt. 
Remark: at this stage, the reaction mixture can be kept at -20 °C overnight 
before work-up if required. Half of the solvent was removed under 
vacuum and EtOAc (800 mL) was added. The reaction mixture was 
washed with Na2S2O3 (sat. aq., 2 x 150 mL), water (2 x 150 mL), brine (1 x 
150 mL), dried over MgSO4, filtered over cotton wool and concentrated 
under vacuum using a rotary evaporator. The resulting oil was dissolved 
in hot heptane/EtOAc (80:20) solution and was hot filtered over a pad of 
silica (⌀ 6, h 4 cm, sintered glass funnel porosity 3), which was washed 
with the same hot solvent until the filtrate was colourless. The filtrate was 
then concentrated under vacuum using a rotary evaporator to give the 
crude product. This was dissolved into heptane (100 mL), the solution was 
heated at reflux, allowed to cool to rt and then kept at -20 °C overnight. 
Using a cannula, the solution was pumped off from the solid which was 
washed with cooled pentane (-30 °C, 2 x 40 mL). The solution was pumped 
off using a cannula. The resulting solid was dried under high-vacuum (2 
mbar) to give the title product as an orange solid (35.9 g, 88%). Rf (eluent: 
PET-EtOAc 80:20) = 0.68. Mp 137-139 °C. Analytical data analogous to 
those reported previously.13 
νmax (film)/cm−1 2971, 1619, 1456, 1368, 1315, 1298, 1206, 1036, 811, 
686.  
1H NMR (500 MHz, CDCl3): δ (ppm) 4.36 (q, J = 1.7, 1.1 Hz, 1H, FcCH), 4.28 
(s, 5H, Cp), 4.22 (q, J = 2.0, 1.1 Hz, 1H, FcCH), 4.11 (t, J = 2.4 Hz, 1H, FcCH), 
3.55 (t, J = 5.5 Hz, 1H, CH), 3.33 (t, J = 5.5 Hz, 1H, CH), 1.45 (s, 6H, 2 x CH3), 
1.03 (d, J = 5.5 Hz, 3H, CH3), 0.92 (d, J = 5.5 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3): δ (ppm) 166.3 (C=O), 92.6 (FcC), 73.6 (FcCH), 
72.7 (Cp), 67.6 (FcCH), 66.8 (FcCH), 50.8 (CH), 45.9 (CH), 40.5 (FcC-I), 21.0 
(2 x CH3), 20.8 (CH3), 20.7 (CH3). 
Mass: 439 [M], 311 [M-CONiPr2], 268. 
(±)-2-iodo-N,N-diisopropylferrocenecarboxamide ((±)-2) by using 
LiTMP-ZnCl2 
[CAS Reg. No. 344927-04-4] 
nBuLi (1.4 M, 71.4 mL, 100 mmol, 2.00 equiv) was added dropwise by 
cannula to a solution of TMPH (16.9 mL, 14.1 g, 100 mmol, 2.00 equiv) in 
THF (80.0 mL) at -20 °C. After addition, the reaction mixture was stirred 
at the same temperature for 10 min. The reaction mixture was cooled to -
30 °C and was cannulated onto a solution of compound 1 (15.7 g, 50.0 
mmol, 1.00 equiv) and ZnCl2 (6.81 g, 50.0 mmol, 1.00 equiv) in THF (100 
mL) at -30 °C. The LiTMP flask was washed with THF (10 mL). The 
reaction mixture was warmed to -10 °C over 2h and a solution of iodine 
(25.4 g, 100 mmol, 2.00 equiv) in THF (130 mL) was added by cannula. 
The iodine flask was washed with THF (10 mL). The cooling bath was 
removed and the reaction mixture was warmed to rt. Half of the solvent 
was removed under vacuum and EtOAc (430 mL) was added. By following 
a similar work-up procedure as the one described before, adjusting the 
quantities, the title product was obtained as an orange solid (20.5 g, 93%). 
Analytical data analogous to those reported above.  
(Sp)-2-iodo-N,N-diisopropylferrocenecarboxamide ((Sp)-2) 
(+)-Sparteine surrogate (1.16 g, 6.00 mmol, 1.30 equiv) and anhydrous 
Et2O (70.0 mL) were introduced into a 250 mL flame-dried round-bottom 
flask under argon. The reaction mixture was cooled to between -85 and -
80 °C (external temperature) in an acetone/liquid nitrogen bath. nBuLi 
(1.4 M, 4.30 mL, 6.00 mmol, 1.30 equiv) was then introduced dropwise by 
syringe, keeping the temperature of the bath between -85 and -80 °C. After 
addition, the reaction mixture was stirred at the same temperature for 30 
min. Compound 1 (1.40 g, 4.50 mmol, 1.00 equiv) was introduced into a 
separate 20 mL flame-dried round-bottom flask which was subjected to 
three cycles of vacuum/argon. Anhydrous toluene (10.0 mL) was added 
and the solution was stirred until dissolution of all solids had occurred. 
The solution of 1 was transferred into the nBuLi/(+)-Sparteine surrogate 
solution dropwise by cannula, keeping the temperature of the bath 
between -85 and -80 °C. The flask was washed with 2.0 mL of anhydrous 
Et2O, also transferred by cannula. After addition, the reaction mixture was 
stirred at the same temperature for 2 h. Iodine (2.30 g, 9.00 mmol, 2.00 
equiv) was introduced into a separate 100 mL flame-dried round-bottom 
flask under argon and was dissolved into anhydrous Et2O (60.0 mL). The 
iodine solution was transferred to the lithioferrocene solution dropwise 
by cannula, keeping the temperature of the bath between -85 and -80 °C. 
The flask was washed with 5.0 mL of anhydrous Et2O, also transferred by 
cannula. The reaction mixture was then allowed to warm to -15 °C, 
keeping the flask into the bath. At -15 °C, the cooling bath was removed 
and the reaction mixture was warmed to rt. Na2S2O3 (sat. aq., 100 mL), 
EtOAc (100 mL) and water (50 mL) were added to the reaction mixture, 
layers were separated and the aqueous one was backwashed with EtOAc 
(50 mL). The organic layer was washed with H3PO4 (5% aq., 3 x 30 mL) 
and the combined aqueous layers were backwashed with EtOAc (50 mL). 
The combined organic layers were washed with water (2 x 50 mL), brine 
(1 x 50 mL), dried over MgSO4, filtered over cotton wool and concentrated 
under vacuum using a rotary evaporator to give the crude product. This 
was purified by column chromatography over SiO2, using PET-EtOAc 
(10:1 to 9:1) to give the title product as an orange oil (1.4 g, 69%, 96:4 er). 
Analytical data analogous to racemic compound. [α]D -87.9 (c 0.01 in 
CHCl3). The enantiomeric ratio was determined on Chiralpak IC-3 column, 
hexane-iPrOH: 98:2, 1.5 mL/min, 20 °C, λ = 254 nm, t (major) = 10.19 min, 
t (minor) = 7.64 min). Recrystallization from hot heptane as described for 
the racemic product increased the er to 99:1 as determined by chiral 
HPLC. CCDC 1898624. 
 
 
General procedure A: Suzuki-Miyaura cross-coupling of (±)-2 
Compound (±)-2 (242 mg, 0.55 mmol, 1.00 equiv), arylboronic acid (2.20 
mmol, 4.00 equiv), Pd(dba)2 (15.8 mg, 27.5 μmol, 5 mol%), CsF (167 mg, 
1.10 mmol, 2.00 equiv) and PPh3 (28.5 mg, 0.11 mmol, 0.20 equiv) were 
placed in a dried Schlenk tube, subjected to three cycles of vacuum/argon. 
Toluene (5.00 mL) was added and the reaction mixture was stirred 
overnight at 120 °C (external temperature) in a pre-heated oil bath. The 
reaction mixture was cooled to rt, water (10 mL) was added and the 
reaction mixture was extracted with EtOAc (2 x 10 mL). The combined 
organic layers were dried over MgSO4, filtered over cotton wool and 
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concentrated under vacuum using a rotary evaporator to give the crude 
product. This was purified by column chromatography over SiO2, using 
PET-EtOAc (proportions given for each product) to give the title product. 
(±)-N,N-Diisopropyl-2-phenylferrocenecarboxamide ((±)-4) 
By following the general procedure A, using phenylboronic acid (268 mg), 
(±)-4 was obtained after column chromatography (PET-EtOAc, 90:10) as 
an orange solid (125 mg, 58.5%). Rf (eluent: PET-EtOAc 90:10) = 0.54. Mp 
134-136 °C. CCDC 1909912. 
νmax (film)/cm−1 2965, 1626, 1463, 1442, 1343, 1317, 1304, 1215, 1136, 
1105, 1035, 818, 765, 698. 
1H NMR (500 MHz, CDCl3): δ (ppm) 7.52 (d, J = 8.0 Hz, 2H, 2 x ArCH), 8.23 
(m, 2H, 2 x ArCH), 7.17 (d, J = 7.1 Hz, 1H, ArCH), 4.45 (dd, J = 1.4, 2.0 Hz, 
1H, FcCH), 4.41 (dd, J = 1.4, 2.0 Hz, 1H, FcCH), 4.24-4.23 (m, 6H, Cp + FcCH), 
3.47 (sept, J = 6.7 Hz, 1H, CH), 3.19 (sept, J = 6.8 Hz, 1H, CH), 1.47 (d, J = 6.8 
Hz, 3H, CH3), 1.38 (d, J = 6.8 Hz, 3H, CH3), 0.81 (d, J = 6.7 Hz, 3H, CH3), 0.24 
(d, J = 6.7 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3): δ (ppm) 168.2 (C=O), 138.3 (ArC), 128.3 (2 x 
ArCH), 128.2 (2 x ArCH), 126.7 (ArCH), 90.1 (FcC-CO), 84.9 (FcC), 71.4 
(Cp), 69.8 (FcCH), 67.0 (FcCH), 64.9 (FcCH), 50.8 (CH), 45.9 (CH), 21.4 
(CH3), 21.1 (CH3), 19.9 (CH3), 19.5 (CH3). 
Mass: 389 [M], 289 [M-NiPr2]. 
(±)-N,N-Diisopropyl-2-(4-methoxyphenyl)ferrocenecarboxamide 
((±)-5) 
By following the general procedure A, using 4-methoxyphenylboronic 
acid (334 mg), (±)-5 was obtained after column chromatography (PET-
EtOAc, 10:1) as an orange solid (197 mg, 77%). Rf (eluent: PET-EtOAc 
80:20) = 0.57. Mp 142-144 °C. CCDC 1909910. 
νmax (film)/cm−1 2962, 2931, 1625, 1460, 1437, 1341, 1314, 1305, 1289, 
1243, 1106, 1027, 906, 845, 815, 734. 
1H NMR (500 MHz, CDCl3): δ (ppm) 7.45 (d, J = 8.8 Hz, 2H, 2 x ArCH), 6.79 
(d, J = 8.8 Hz, 2H, 2 x ArCH), 4.41 (dd, J = 1.5, 2.2 Hz, 1H, FcCH), 4.38 (dd, J 
= 1.5, 2.2 Hz, 1H, FcCH), 4.23 (s, 5H, Cp), 4.20 (t, J = 2.2 Hz, 1H, FcCH), 3.78 
(s, 3H, OCH3), 3.48 (sept, J = 6.7 Hz, 1H, CH), 3.20 (sept, J = 6.7 Hz, 1H, CH), 
1.48 (d, J = 6.7 Hz, 3H, CH3), 1.38 (d, J = 6.7 Hz, 3H, CH3), 0.83 (d, J = 6.7 Hz, 
3H, CH3), 0.30 (d, J = 6.7 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3): δ (ppm) 168.3 (C=O), 158.6 (ArC-O), 130.4 
(ArC), 129.3 (2 x ArCH), 113.7 (2 x ArCH), 89.3 (FcC-CO), 85.1 (FcC), 71.3 
(Cp), 69.4 (FcCH), 66.6 (FcCH), 64.9 (FcCH), 55.4 (OCH3), 50.8 (CH), 45.8 
(CH), 21.3 (CH3), 21.0 (CH3), 19.9 (CH3), 19.7 (CH3). 
Mass: 491 [M], 319 [M-NiPr2]. 
(±)-N,N-Diisopropyl-2-(2,4-dimethoxyphenyl)ferrocene-
carboxamide ((±)-6) 
[CAS Reg. No. 173911-02-9] 
By following the general procedure A, using 2,4-dimethoxyphenylboronic 
acid (400 mg), (±)-6 was obtained after column chromatography (PET-
EtOAc, 10:1) as an orange solid (174 mg, 64%). Rf (eluent: PET-EtOAc 
80:20) = 0.59. Mp 163-166 °C. Analytical data analogous to those reported 
previously.7 CCDC 1909911. 
νmax (film)/cm−1 2964, 1625, 1505, 1450, 1341, 1310, 122, 1037, 1104, 
809, 735. 
1H NMR (500 MHz, CDCl3): δ (ppm) 7.43 (d, J = 2.6 Hz, 1H, ArCH), 6.75-
6.70 (m, 2H, 2 x ArCH), 4.63 (dd, J = 1.5, 2.3 Hz, 1H, FcCH), 4.41 (dd, J = 1.5, 
2.2 Hz, 1H, FcCH), 4.26 (s, 5H, Cp), 4.25 (t, J = 2.2 Hz, 1H, FcCH), 3.79 (s, 
3H, OCH3), 3.71 (s, 3H, OCH3),  3.53 (sept, J = 6.7 Hz, 1H, CH), 3.16 (sept, J 
= 6.7 Hz, 1H, CH), 1.45 (d, J = 6.7 Hz, 3H, CH3), 1.32 (d, J = 6.7 Hz, 3H, CH3), 
0.82 (d, J = 6.7 Hz, 3H, CH3), 0.28 (d, J = 6.7 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3): δ (ppm) 168.2 (C=O), 153.3 (ArC-O), 151.5 
(ArC-O), 127.1 (ArC), 117.4 (ArCH), 113.5 (ArCH), 112.1 (ArCH), 90.8 
(FcC-CO), 81.5 (FcC), 71.3 (Cp), 69.0 (FcCH), 68.7 (FcCH), 66.7 (FcCH), 
56.1 (OCH3), 55.8 (OCH3), 50.6 (CH), 45.7 (CH), 21.2 (CH3), 21.1 (CH3), 20.3 
(CH3), 19.7 (CH3). 
Mass: 449 [M], 349 [M-NiPr2]. 
(±)-N,N-Diisopropyl-2-(2-naphthyl)ferrocenecarboxamide ((±)-7) 
By following the general procedure A, using 2-naphthylboronic acid (378 
mg), (±)-7 was obtained after column chromatography (PET-EtOAc, 
90:10) as an orange solid (156 mg, 64.5%). Rf (eluent: PET-EtOAc 90:10) 
= 0.43. Mp 218-220 °C. CCDC 1909914. 
νmax (film)/cm−1 2966, 1622, 1462, 1334, 1303, 1201, 1134, 1040, 864, 
820, 808, 755. 
1H NMR (500 MHz, CDCl3): δ (ppm) 7.94 (s, 1H, ArCH), 7.78-7.74 (m, 2H, 2 
x ArCH), 7.74 (m, 2H, 2 x ArCH), 7.45-7.40 (m, 2H, 2 x ArCH), 4.61 (dd, J = 
1.5, 2.3 Hz, 1H, FcCH), 4.49 (dd, J = 1.4, 2.3 Hz, 1H, FcCH), 4.32 (t, J = 2.3 
Hz, 1H, FcCH), 3.55 (sept, J = 6.7 Hz, 1H, CH), 3.20 (sept, J = 6.8 Hz, 1H, CH), 
1.52 (d, J = 6.8 Hz, 3H, CH3), 1.43 (d, J = 6.8 Hz, 3H, CH3), 0.84 (d, J = 6.7 Hz, 
3H, CH3), 0.19 (d, J = 6.7 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3): δ (ppm) 168.3 (C=O), 136.1 (ArC), 133.6 (ArC), 
132.5 (ArC), 127.9 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.1 (ArCH), 
126.4 (ArCH), 125.8 (ArCH), 125.6 (ArCH), 90.3 (FcC-CO), 84.5 (FcC), 71.5 
(Cp), 70.2 (FcCH), 67.3 (FcCH), 65.0 (FcCH), 50.9 (CH), 45.9 (CH), 21.4 
(CH3), 21.1 (CH3), 20.0 (CH3), 19.8 (CH3). 
Mass: 439 [M], 339 [M-NiPr2]. 
(±)-2-(2-Chlorophenyl)-N,N-diisopropylferrocenecarboxamide ((±)-
8) 
By following the general procedure A, using 2-chlorophenylboronic acid 
(344 mg), (±)-8 was obtained after column chromatography (PET-EtOAc, 
10:1) as an orange solid (29.2 mg, 11%). Rf (eluent: PET-EtOAc 90:10) = 
0.34. Mp 82-84 °C. 
νmax (film)/cm−1 2994, 2960, 2929, 1621, 1461, 1437, 1368, 1339, 1305, 
1212, 1195, 1157, 1136, 1035, 1023, 1003, 813, 749. 
1H NMR (500 MHz, CDCl3): δ (ppm) 8.03 (dd, J = 1.5, 7.8 Hz, 1H, ArCH), 
7.29 (dd, J = 0.8, 7.8 Hz, 1H, ArCH), 7.22 (dt, J = 1.1, 7.7 Hz, 1H, ArCH), 7.16 
(dt, J = 1.5, 7.7 Hz, 1H, ArCH), 4.70 (dd, J = 1.0, 2.0 Hz, 1H, FcCH), 4.46 (dd, 
J = 1.4, 2.0 Hz, 1H, FcCH), 4.31 (t, J = 2.4 Hz, 1H, FcCH), 4.29 (s, 5H, Cp), 
3.51 (sept, J = 6.6 Hz, 1H, CH), 3.13 (sept, J = 6.8 Hz, 1H, CH), 1.44 (d, J = 6.8 
Hz, 3H, CH3), 1.21 (d, J = 6.8 Hz, 3H, CH3), 0.85 (d, J = 6.6 Hz, 3H, CH3), 0.30 
(d, J = 6.6 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3): δ (ppm) 167.6 (C=O), 135.9 (ArC), 134.0 
(ArCH), 133.5 (ArC), 129.6 (ArCH), 128.0 (ArCH), 126.4 (ArCH), 91.9 (FcC-
CO), 83.2 (FcC), 71.5 (Cp), 68.9 (FcCH), 68.8 (FcCH), 66.6 (FcCH), 50.7 
(CH), 45.8 (CH), 21.3 (CH3), 21.2 (CH3), 19.9 (CH3), 19.6 (CH3).    
Mass: 313 [M-C6H4Cl+H], 213 [FcCO2H]. 
(±)-2-(3-Chlorophenyl)-N,N-diisopropylferrocenecarboxamide ((±)-
9) 
By following the general procedure A, using 3-chlorophenylboronic acid 
(344 mg), (±)-9 was obtained after column chromatography (PET-EtOAc, 
10:1) as an orange solid (66.6 mg, 28.5%). Rf (eluent: PET-EtOAc 90:10) = 
0.46. Mp 133-135 °C. CCDC 1909913. 
νmax (film)/cm−1 2972, 1617, 1597, 1461, 1439, 1368, 1341, 1310, 1196, 
1136, 1055, 1039, 1005, 819, 810, 798, 768, 687. 
1H NMR (500 MHz, CDCl3): δ (ppm) 7.51 (t, J = 1.8 Hz, 1H, ArCH), 7.42 (dt, 
J = 1.9, 6.6 Hz, 1H, ArCH), 7.17 (d, J = 4.7 Hz, 1H, ArCH), 7.16 (t, J = 1.8 Hz, 
1H, ArCH), 4.45 (m, 1H, FcCH), 4.44 (m, 1H, FcCH), 4.28 (t, J = 2.4 Hz, 1H, 
FcCH), 4.25 (s, 5H, Cp), 3.47 (sept, J = 6.7 Hz, 1H, CH), 3.24 (sept, J = 6.8 Hz, 
1H, CH), 1.50 (d, J = 6.8 Hz, 3H, CH3), 1.42 (d, J = 6.8 Hz, 3H, CH3), 0.85 (d, J 
= 6.7 Hz, 3H, CH3), 0.35 (d, J = 6.7 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3): δ (ppm) 167.8 (C=O), 140.7(ArC), 134.2 (ArC), 
129.5 (ArCH), 127.9 (ArCH), 126.7 (ArCH), 126.3 (ArCH), 90.3 (FcC-CO), 
83.2 (FcC), 71.6 (Cp), 70.1 (FcCH), 67.4 (FcCH), 64.9 (FcCH), 50.9 (CH), 
46.0 (CH), 21.3 (CH3), 21.1 (CH3), 20.0 (CH3), 19.7 (CH3).    
Mass: 423 [M], 323 [M-NiPr2], 296 [M-CONiPr2 + H]. 
(±)-N,N-Diisopropyl-2-(4-trifluoromethylphenyl)ferrocene-
carboxamide ((±)-10) 
By following the general procedure A, using 4-
(trifluoromethyl)phenylboronic acid (417 mg), (±)-10 was obtained after 
column chromatography (PET-EtOAc, 10:1) as an orange solid (52.0 mg, 
20.5%). Rf (eluent: PET-EtOAc 90:10) = 0.50. Mp 179-181 °C. CCDC 
1909915. 
νmax (film)/cm−1 2965, 2932, 2234, 1613, 1463, 1319, 1162, 1121, 1106, 
1068, 906, 818, 727. 
1H NMR (500 MHz, CDCl3): δ (ppm) 7.65 (d, J = 8.0 Hz, 2H, 2 x ArCH), 7.49 
(d, J = 8.0 Hz, 2H, 2 x ArCH), 4.50 (s, 1H, FcCH), 4.47 (s, 1H, FcCH), 4.32 (s, 
1H, FcH), 4.25 (s, 5H, Cp), 3.48 (sept, J = 6.7 Hz, 1H, CH), 3.25 (sept, J = 6.7 
Hz, 1H, CH), 1.50 (d, J = 6.7 Hz, 3H, CH3), 1.40 (d, J = 6.7 Hz, 3H, CH3), 0.87 
(d, J = 6.7 Hz, 3H, CH3), 0.34 (d, J = 6.7 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3): δ (ppm) 167.8 (s, C=O), 142.9 (s, ArC), 128.6 
(q, J = 32.6 Hz, ArC-CF3), 128.2 (s, 2 x ArCH), 124.5 (q, J = 271.9 Hz, CF3), 
125.2 (q, J = 3.5 Hz, 2 x ArCH), 90.7 (s, FcC-CO), 82.9 (s, FcC), 71.7 (s, Cp), 
70.3 (s, FcCH), 67.6 (s, FcCH), 65.1 (s, FcCH), 50.9 (s, CH), 46.0 (s, CH),  21.3 
(s, CH3), 21.0 (s, CH3), 20.1 (s, CH3), 19.8 (s, CH3). 
19F NMR (282 MHz, CDCl3): δ (ppm) -62.4 (s). 
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Mass: 457 [M], 357 [M-NiPr2], 330 [M-CONiPr2 + H]. 
General procedure B: Ullmann-type cross-coupling of (±)-2 
Compound (±)-2 (263 mg, 0.60 mmol, 1.00 equiv), carboxylic acid 
(0.72 mmol, 1.20 equiv) and Cu2O (103 mg, 0.72 mmol, 1.20 equiv) were 
placed in a dried Schlenk tube, subjected to three cycles of vacuum/argon. 
Acetonitrile (8.50 mL) was added and the reaction mixture was stirred 
overnight at 90 °C (external temperature) in a pre-heated oil bath. The 
reaction mixture was cooled to rt, filtered over a pad of Celite, washed 
with EtOAc until colorless.  The filtrate was concentrated under vacuum 
using a rotary evaporator to give the crude product. This was purified by 
column chromatography over SiO2, using PET-EtOAc (proportions given 
for each product) to give the title product. 
(±)-N,N-Diisopropyl-2-(4-fluorobenzoyl)ferrocenecarboxamide 
((±)-11) 
By following the general procedure B, using 4-fluorobenzoic acid (101 
mg), (±)-11 was obtained after column chromatography (PET-EtOAc, 
10:1 to 90:10, 1% of NEt3) as an orange solid (230 mg, 85%). Rf (eluent: 
PET-EtOAc 90:10) = 0.50. Mp 142-144 °C. CCDC 1909916. 
νmax (film)/cm−1 2967, 1744, 1736, 1632, 1598, 1507, 1471, 1435, 1371, 
1321, 1262, 1246, 1224, 1155, 1134, 1081, 1063, 1041, 1012, 1003, 866, 
812, 763, 757, 686. 
1H NMR (300 MHz, CDCl3): δ (ppm) 8.10 (dd, J = 5.5, 8.9 Hz, 2H, 2 x ArCH), 
7.11 (t, J = 8.6 Hz, 2H, 2 x ArCH), 4.64 (dd, J = 1.5, 2.6 Hz, 1H, FcCH), 4.38 
(s, 5H, Cp), 4.12 (dd, J = 1.5, 2.7 Hz, 1H, FcCH), 4.06 (br s, 1H, CH), 4.00 (t, 
J = 2.7 Hz, 1H, FcCH), 3.36 (br s, 1H, CH), 1.45 (br s, 3H, CH3), 1.37 (br s, 
3H, CH3), 1.05 (br s, 3H, CH3), 0.99 (br s, 3H, CH3). 
13C NMR (75.4 MHz, CDCl3): δ (ppm) 166.2 (d, J = 254.7 Hz, ArC-F), 165.8 
(s, C=Oamide), 164.4 (s, C=Oester), 132.7 (d, J = 9.4 Hz, 2 x ArCH), 126.0 (d, J 
= 2.8 Hz, ArC), 115.9 (d, J = 22.2 Hz, 2 x ArCH), 115.2 (s; FcC-O), 80.1 (s, 
FcC), 71.4 (s, Cp), 62.8 (s, FcCH), 62.1 (s, FcCH), 61.1 (s, FcCH), 50.7 (s, CH), 
46.1 (s, CH), 20.8 (s, 4 x CH3). 
Mass: 451 [M], 328, 229. 
(Sp)-N,N-Diisopropyl-2-(4-fluorobenzoyl)ferrocenecarboxamide ((Sp 
)-11) 
By following the general procedure B, using (Sp)-2-iodo-N,N-
diisopropylferrocenecarboxamide (er 87:13, 80.0 mg) and 4-
fluorobenzoic acid (30.3 mg), (Sp)-11 was obtained after column 
chromatography (PET-EtOAc, 10:1 to 90:10, 1% of NEt3) as an orange 
solid (62 mg, 76%, 89:11 er). [α]D -1.09 (c 0.01 in CHCl3). The 
enantiomeric ratio was determined on Chiralpak IC-3 column, hexane-
iPrOH: 98:2, 1.0 mL/min, 20 °C, λ = 254 nm, t (major) = 16.50 min, t 
(minor) = 19.41 min. 
(±)-N,N-Diisopropyl-2-(2-naphthoyl)ferrocenecarboxamide ((±)-
12) 
By following the general procedure B, using 2-naphthoic acid (126 mg), 
(±)-12 was obtained after column chromatography (PET-EtOAc, 10:1 to 
90:10, 1% of NEt3) as an orange solid (290 mg, quant.). Rf (eluent: PET-
EtOAc 90:10) = 0.43. Mp 145-147 °C. 
νmax (film)/cm−1 2978, 1732, 1626, 1472, 1429, 1318, 1265, 1217, 1189, 
1134, 1082, 1004, 951, 876, 834, 814, 778. 
1H NMR (300 MHz, CDCl3): δ (ppm) 8.67 (s, 1H, ArCH), 8.10 (dd, J = 1.7, 8.6 
Hz, 1H, ArCH), 7.96 (d, J = 8.6 Hz, 1H, ArCH), 7.89 (d, J = 6.2 Hz, 1H, ArCH), 
7.87 (d, J = 5.4 Hz, 1H, ArCH), 7.56 (m, 2H, 2 x ArCH), 4.75 (dd, J = 1.4, 2.5 
Hz, 1H, FcCH), 4.43 (s, 5H, Cp), 4.16 (dd, J = 1.4, 2.5 Hz, 1H, FcCH), 4.08 (br 
s, 1H, CH), 4.04 (t, J = 2.7 Hz, 1H, FcCH), 3.39 (br s, 1H, CH), 1.47 (br s, 6H, 
2 x CH3), 1.02 (br s, 6H, 2 x CH3). 
13C NMR (75.4 MHz, CDCl3): δ (ppm) 165.8 (s, C=Oamide), 165.4 (s, C=Oester), 
135.9 (ArC), 132.7 (ArC), 131.8 (ArCH), 129.7 (ArCH), 128.7 (ArCH), 128.5 
(ArCH), 127.9 (ArCH), 126.9 (ArCH), 125.5 (ArCH), 114.9 (FcC-O), 80.6 
(FcC), 71.4 (Cp), 62.9 (FcCH), 62.1 (FcCH), 61.0 (FcCH), 50.7 (CH), 46.1 
(CH), 20.9 (4 x CH3). 
Mass: 313 [M-C11H7O2 + H]. 
 
(±)-N,N-Diisopropyl-2-(2,4-dimethylbenzoyl)ferrocenecarboxamide 
((±)-13) 
By following the general procedure B, using 2,4-dimethylbenzoic acid 
(108 mg), (±)-13 was obtained after column chromatography (PET-
EtOAc, 90:10, 1% of NEt3) as an orange solid (242 mg, 87%). Rf (eluent: 
PET-EtOAc 10:1) = 0.28. Mp 152-154 °C. CCDC 1909919. 
νmax (film)/cm−1 2958, 1715,1620, 1463, 1430, 1323, 1288, 1252, 1236,  
1H NMR (300 MHz, CDCl3): δ (ppm) 7.95 (d, J = 8.4 Hz, 1H, ArCH), 7.07-
7.05 (m, 2H, 2 x ArCH), 4.60 (dd, J = 1.5, 2.6 Hz, 1H, FcCH), 4.39 (s, 5H, Cp), 
4.12 (dd, J = 1.5, 2.6 Hz, 1H, FcCH), 4.06 (br s, 1H, CH), 4.00 (t, J = 2.6 Hz, 
1H, FcCH), 3.35 (br s, 1H, CH), 2.59 (s, 3H, CH3), 2.34 (s, 3H, CH3), 1.46 (br 
s, 3H, CH3), 1.38 (br s, 3H, CH3), 1.03 (br s, 3H, CH3), 0.98 (br s, 3H, CH3). 
13C NMR (75.4 MHz, CDCl3): δ (ppm) 166.2 (C=O), 165.9 (C=O), 143.3 
(ArC), 141.0 (ArC), 132.7 (ArCH), 131.7 (ArCH), 126.8 (ArCH), 125.9 
(ArC), 114.9 (FcC-O), 80.7 (FcC), 71.3 (Cp), 62.8 (FcCH), 62.1 (FcCH), 61.2 
(FcCH), 50.7 (CH), 46.0 (CH), 22.0 (CH3), 21.6 (CH3), 20.8 (2 x CH3). 
Mass: 461 [M]. 
(±)-2-(2-Acetoxyphenyl)-N,N-diisopropylferrocenecarboxamide 
((±)-14) 
By following the general procedure B, using 2-acetoxybenzoic acid (130 
mg), (±)-14 was obtained after column chromatography (PET-EtOAc, 
10:1 to 90:10, 1% of NEt3) as an orange solid (212 mg, 72%). Rf (eluent: 
PET-EtOAc 90:10) = 0.42. Mp 157-159 °C. CCDC 1909918. 
νmax (film)/cm−1 2966, 1764, 1736, 1624, 1604, 1474, 1431, 1321, 1242, 
1212, 1182, 1156, 1051, 1002, 911, 818, 754, 696. 
1H NMR (300 MHz, CDCl3): δ (ppm) 8.13 (dd, J = 1.7, 7.8 Hz, 1H, ArCH), 
7.56 (dt, J = 1.7, 7.8 Hz, 1H, ArCH), 7.32 (dt, J = 1.7, 7.8 Hz, 1H, ArCH), 7.09 
(dd, J = 1.7, 7.8 Hz, 1H, ArCH), 4.56 (dd, J = 1.4, 2.5 Hz, 1H, FcCH), 4.38 (s, 
5H, Cp), 4.12 (dd, J = 1.4, 2.6 Hz, 1H, FcCH), 4.04 (br s, 1H, CH), 4.00 (t, J = 
2.6 Hz, 1H, FcCH), 3.34 (br s, 1H, CH), 2.34 (CH3), 1.44 (br s, 3H, CH3), 1.38 
(br s, 3H, CH3), 1.02 (br s, 3H, CH3), 0.96 (br s, 3H, CH3). 
13C NMR (75.4 MHz, CDCl3): δ (ppm) 169.6 (C=Oacetate), 165.6 (C=Oamide), 
163.1 (C=Oester), 151.1 (ArC), 134.5 (ArCH), 132.3 (ArCH), 126.3 (ArCH), 
124.1 (ArCH), 122.6 (ArC-O), 114.7 (FcC-O), 80.4 (FcC), 71.3 (Cp), 62.9 
(FcCH), 62.1 (FcCH), 61.2 (FcCH), 50.6 (CH), 46.0 (CH), 21.2 (CH3), 20.7 (2 
x CH3). 
Mass: 491 [M], 329 [M-C9H7O3 + H]. 
Bis (±)-N,N-Diisopropyl-2-(1,4-phenyldioyl)ferrocenecarboxamide 
((±)-15) 
By following the general procedure B, using terephtalic acid (49.8 mg, 0.30 
mmol, 0.50 equiv), (±)-15 was obtained after column chromatography 
(PET-EtOAc, 10:1 to 90:10, 1% of NEt3) as a red solid (193 mg, 49%). Rf 
(eluent: PET-EtOAc 10:1) = 0.18. Mp 70-75 °C. 
νmax (film)/cm−1 2965, 1737, 1627, 1464, 1431, 1319, 1241, 1211, 1134, 
1085, 1017, 814, 720. 
1H NMR (300 MHz, CDCl3): δ (ppm) 8.18 (s, 2H, 2 x ArCH), 8.17 (s, 2H, 2 x 
ArCH), 4.69 (dd, J = 1.4, 2.4 Hz, 2H, 2 x FcCH), 4.40 (s, 10H, 2x Cp), 4.15 
(dd, J = 1.2, 2.4 Hz, 2H, 2 x FcCH), 4.09 (br s, 2H, 2 x CH), 4.03 (t, J = 2.6 Hz, 
2H, 2 x FcCH), 3.39 (br s, 2H, 2 x CH), 1.47 (br s, 6H, 2 x CH3), 1.41 (br s, 
6H, 2 x CH3), 1.06 (br s, 6H, 2 x CH3), 1.02 (br s, 6H, 2 x CH3). 
13C NMR (75.4 MHz, CDCl3): δ (ppm) 165.6 (2 x C=Oamide), 164.3 (C=Oester), 
164.2 (C=Oester), 133.7 ( 2 x ArC), 130.0 (4 x ArCH), 115.0 (FcC-O), 114.9 
(FcC-O), 79.9 (2 x FcC), 71.3 (2 x Cp), 62.8 (FcCH), 62.7 (FcCH), 62.0 (2 x 
FcCH), 60.8 (FcCH), 60.7 (FcCH), 55.5 (CH), 50.5 (CH), 45.9 (2 x CH), 20.7 
(8 x CH3). 
(±)-N,N-Diisopropyl-2-(ferrocenoyl)ferrocenecarboxamide ((±)-16) 
By following the general procedure B, using ferrocenecarboxylic acid (165 
mg), (±)-16 was obtained after column chromatography (PET-EtOAc, 
90:10, 1% of NEt3) as an orange solid (277 mg, 85%). Rf (eluent: PET-
EtOAc 10:1) = 0.26. Mp 58-62 °C. CCDC 1909917. 
νmax (film)/cm−1 2959, 1727, 1626, 1467, 1429, 1374, 1317, 1267, 1245, 
1134, 1104, 1027, 1002, 910, 817, 804. 
1H NMR (300 MHz, CDCl3): δ (ppm) 4.85 (m, 1H, FcCH), 4.83 (m, 1H, FcCH), 
4.61 (dd, J = 1.5, 2.5 Hz, 1H, FcCH), 4.43 (t, J = 1.7 Hz, 2H, 2 x FcCH), 4.39 
(s, 5H, Cp), 4.28 (s, 5H, Cp), 4.09 (dd, J = 1.5, 2.5 Hz, 1H, FcCH), 4.02 (br s, 
1H, CH), 3.98 (t, J = 2.5 Hz, 1H, FcCH), 3.40 (br s, 1H, CH), 1.50 (br s, 6H, 2 
x CH3), 1.05 (br s, 6H, 2 x CH3). 
13C NMR (75.4 MHz, CDCl3): δ (ppm) 169.7 (2 x C=Oester), 165.7 (C=Oamide), 
114.5 (FcC-O), 80.2 (FcC-COamide), 71.7 (2 x FcCH), 71.1 (Cp), 70.4 (2 x 
FcCH), 70.3 (FcC-COester), 70.0 (Cp), 62.5 (FcCH), 61.9 (FcCH), 60.6 (FcCH), 
50.6 (CH), 45.8 (CH), 21.0 (4 x CH3). 
(±)-N,N-Diisopropyl-2-(2-thiophenoyl)ferrocenecarboxamide ((±)-
17) 
By following the general procedure B, using 2-thiophenecarboxylic acid 
(92.3 mg), (±)-17 was obtained after column chromatography (PET-
EtOAc, 10:1, 1% of NEt3) as an orange solid (204 mg, 77%). Rf (eluent: 
PET-EtOAc 90:10) = 0.40. Mp 118-120 °C. 
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νmax (film)/cm−1 2966, 1721, 1632, 1615, 1463, 1410, 1357, 1317, 1247, 
1223, 1208, 1079, 1057, 1038, 1022, 1001, 812, 742, 735. 
1H NMR (300 MHz, CDCl3): δ (ppm) 7.86 (dd, J = 1.3, 3.8 Hz, 1H, ArCH), 
7.59 (dd, J = 1.3, 5.0 Hz, 1H, ArCH), 7.11 (dd, J = 3.8, 5.0 Hz, 1H, ArCH), 4.66 
(dd, J = 1.5, 2.6 Hz, 1H, FcCH), 4.11 (dd, J = 1.5, 2.6 Hz, 1H, FcCH), 4.04 (br 
s, 1H, CH), 3.99 (t, J = 2.6 Hz, 1H, FcCH), 3.38 (br s, 1H, CH), 1.44 (br s, 6H, 
2 x CH3), 1.02 (br s, 6H, 2 x CH3). 
13C NMR (75.4 MHz, CDCl3): δ (ppm) 165.6 (C=Oamide), 160.5 (C=Oester), 
134.4 (ArCH), 133.5 (ArCH), 13.1 (ArC), 128.1 (ArCH), 114.6 (FcC-CO), 
80.4 (FcC), 71.4 (Cp), 62.9 (FcCH), 62.1 (FcCH), 60.7 (FcCH), 50.7 (CH), 
46.0 (CH), 20.8 (4 x CH3). 
Mass: 439 [M], 328, 229. 
(±)-N,N-Diisopropyl-2-(3,4-methylenedioxycinnamoyl)ferrocene-
carboxamide ((±)-18) 
By following the general procedure B, using 3,4-methylenedioxycinnamic 
acid (138 mg), (±)-18 was obtained after column chromatography (PET-
EtOAc, 90:10, 1% of NEt3) as an orange solid (267 mg, 88%). Rf (eluent: 
PET-EtOAc 90:10) = 0.22. Mp 153-155 °C. 
νmax (film)/cm−1 2967, 1730, 1628, 1601, 1500, 1490, 1464, 1447, 1430, 
1367, 1317, 1299, 1247, 1136, 1119, 1100, 1032, 1006, 926, 817, 751. 
1H NMR (300 MHz, CDCl3): δ (ppm) 7.64 (d, J = 15.9 Hz, 1H, CH=CH=CO), 
7.04 (d, J = 1.7 Hz, 1H, ArCH), 7.01 (dd, J = 1.7, 7.9 Hz, 1H, ArCH), 6.80 (d, J 
= 7.9 Hz, 1H, ArCH), 6.34 (d, J = 15.9 Hz, 1H, CH=CH=CO), 6.00 (s, 2H, CH2), 
4.56 (dd, J = 1.4, 2.4 Hz, 1H, FcCH), 4.37 (s, 5H, Cp), 4.11 (dd, J = 1.5, 2.6 Hz, 
1H, FcCH), 4.05 (br s, 1H, CH), 3.98 (t, J = 2.6 Hz, 1H, FcCH), 3.37 (br s, 1H, 
CH), 1.45 (br s, 6H, 2 x CH3), 1.04 (br s, 6H, 2 x CH3). 
13C NMR (75.4 MHz, CDCl3): δ (ppm) 165.9 (C=O), 165.8 (C=O), 150.1 (ArC-
O), 148.6 (ArC-O), 145.9 (CH=CH=CO), 128.9 (ArC), 125.0 (ArCH), 115.3 
(CH=CH=CO), 114.8 (FcC-CO), 108.8 (ArCH), 106.8 (ArCH), 101.8 (CH2), 
80.0 (FcC), 71.4 (Cp), 63.0 (FcCH), 62.0 (FcCH), 61.1 (FcCH), 50.7 (CH), 
46.1 (CH), 21.0 (4 x CH3). 
(±)-N,N-Diisopropyl-2-(piperoyl)ferrocenecarboxamide ((±)-19) 
By following the general procedure B, using piperic acid (157 mg), (±)-19 
was obtained after column chromatography (PET-EtOAc, 90:10 to 80:20, 
1% of NEt3) as an orange solid (291 mg, 92%). Rf (eluent: PET-EtOAc 
90:10) = 0.23. Mp 59-64 °C. 
νmax (film)/cm−1 2965, 1722, 162, 1605, 1489, 1446, 1433, 1368, 1320, 
1521, 1227, 1203, 1108, 1036, 997, 928, 814, 754. 
1H NMR (300 MHz, CDCl3): δ (ppm) 7.48 (dd, J = 10.7, 15.2 Hz, 1H, 
CH=CH=CH=CH=CO), 6.99 (d, J = 1.6 Hz, 1H, ArCH), 6.92 (dd, J = 1.6, 8.1 
Hz, 1H, ArCH), 6.84 (d, J = 15.5 Hz, 1H, CH=CH=CH=CH=CO), 6.78 (d, J = 8.1 
Hz, 1H, ArCH), 6.71 (dd, J = 10.7, 15.5 Hz, 1H, CH=CH=CH=CH=CO), 6.01 
(d, J = 15.2 Hz, 1H, CH=CH=CH=CH=CO), 5.98 (s, 2H, CH2), 4.56 (dd, J = 1.5, 
2.5 Hz, 1H, FcCH), 4.37 (s, 5H, Cp), 4.11 (dd, J = 1.5, 2.5 Hz, 1H, FcCH), 4.04 
(br s, 1H, CH), 3.97 (t, J = 2.56 Hz, 1H, FcCH), 3.38 (br s, 1H, CH), 1.46 (br 
s, 6H, 2 x CH3), 1.04 (br s, 6H, 2 x CH3). 
13C NMR (75.4 MHz, CDCl3): δ (ppm) 165.9 (C=Oester), 165.7 (C=Oamide), 
148.9 (ArC-O), 148.5 (ArC-O), 146.4 (CH=CH=CH=CH=CO), 141.3 
(CH=CH=CH=CH=CO), 130.7 (ArC), 124.6 (CH=CH=CH=CH=CO), 123.4 
(CH=CH=CH=CH=CO), 114.6 (FcC-CO), 108.8 (ArCH), 106.2 (ArCH), 101.6 
(CH2), 80.2 (FcC), 71.4 (Cp), 63.1 (FcCH), 62.1 (FcCH), 61.0 (FcCH), 50.7 
(CH), 46.0 (CH), 20.9 (4 x CH3). 
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